The Alliance for mRNA Medicines (AMM) is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. Our mission is to propel the future of mRNA medicine, improve patients’ lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.
NOVEMBER 1st, 2023
Twenty-three of the leading organizations representing the mRNA development, research and manufacturing industries officially announced the launch of the Alliance for mRNA Medicines.
AMM advisors will engage with governments, policymakers, regulators and other stakeholders in North America, Europe and Asia Pacific to advocate for policies that encourage innovation, define regulatory standards, support manufacturing and promote access of mRNA medicines to patients.
AMM members represent some of the most recognized mRNA innovators in the field. Bringing the best minds together, we aim to overcome the most critical obstacles inhibiting the advancement of mRNA research, development and manufacturing. Furthermore, AMM will forge inclusive and collaborative partnerships with other networking forums to co-publish, augment or improve upon technical and scientific content generated by these groups.
The rapid evolution of mRNA medicines since the inception of the COVID vaccine has created a need to (1) elevate the understanding and perception of mRNA medicines to the general public and (2) develop and expand the pool of mRNA talent in the industry. AMM will champion causes and projects to educate the community on the potential of mRNA technologies to improve the human condition and collaborate with institutions to uplevel and standardize the education of mRNA scientists and to retain them in the field.
AMM will serve as the leading convenor of mRNA stakeholders, bringing together innovators in the field to propel the future of mRNA medicine and advance scientific knowledge.
Bloomberg Distinguished Professor of RNA Biology and Therapeutics
Director, Hopkins RNA Innovation Center
Learn More
Interim Director
National Center for Therapeutics Manufacturing Texas A&M Engineering
Learn More
